Registry Study for Optimal Management of Liver Failure in the Chinese Population

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-01-06

Study Completion Date

2028-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Liver failure is the most severe form of liver damage caused by viral, alcoholic, drug-related and ischemia-reperfusion factors, often combined with extrahepatic organ damage, resulting in a high mortality rate. This study intends to construct a real-world case registry database of inpatients with liver failure based on an electronic clinical data collection system through a multicenter collaborative network to study the clinical characteristics, epidemiology of bacterial and fungal infections, the impact of sarcopenia on clinical prognosis, and optimization of treatment strategies such as antiviral and artificial liver in Chinese inpatients with liver failure. The cohort and experience generated from this study will be used as a support for a series of future studies to focus on clinical issues such as infection, end-stage liver disease combined with organ failure, and early warning of critically ill patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prognosis of Patients With Acute-on-chronic Liver Failure

NCT05393453

Acute-On-Chronic Liver Failure

UNKNOWN

A Clinical Study of Portal Vein Embolization and Liver Venous Deprivation

NCT05457374

Liver Venous Deprivation

UNKNOWN NA

Characterization of Metabolomic Fingerprints in Patients With Acute Liver Failure and Acute-on-chronic Liver Failure With Hepatic Encephalopathy

NCT05772585

Hepatic Encephalopathy Acute Liver Failure Acute on Chronic Liver Failure

WITHDRAWN

To Study the Clinical Course and Outcomes of Non-electively Hospitalised Patients of Chronic Liver Disease (CLD) With Hepatic or Extra-hepatic Predominant Organ Failure(s) at 6 Months.

NCT07270809

Chronic Liver Disease

NOT_YET_RECRUITING

SALT for Treatment of Patients With Early ACLF

NCT06069037

Acute-On-Chronic Liver Failure

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ALF

acute liver failure

ALF

Intervention Type PROCEDURE

Acute onset, no history of underlying liver disease, liver failure characterized by degree Ⅱ or above hepatic encephalopathy developed within 2 weeks

SALF

subacute liver failure

SALF

Intervention Type PROCEDURE

The onset was acute, with no history of underlying liver disease, and clinical manifestations of liver failure appeared between 2 and 26 weeks

ACLF

acute-on-chronic liver failure

ACLF

Intervention Type PROCEDURE

On the basis of chronic liver disease, the clinical manifestations of acute liver decompensation and liver failure appear in a short period

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ALF

Acute onset, no history of underlying liver disease, liver failure characterized by degree Ⅱ or above hepatic encephalopathy developed within 2 weeks

Intervention Type PROCEDURE

SALF

The onset was acute, with no history of underlying liver disease, and clinical manifestations of liver failure appeared between 2 and 26 weeks

Intervention Type PROCEDURE

ACLF

On the basis of chronic liver disease, the clinical manifestations of acute liver decompensation and liver failure appear in a short period

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients with a diagnosis consistent with liver failure and pre-liver failure:

* Extreme weakness with significant gastrointestinal symptoms such as anorexia, vomiting and abdominal distention;
* Elevated alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) with progressive jaundice (TBil≥85.5 μmol/L);
* Bleeding tendency with PTA ≤ 60% or INR ≥ 1.5.